Prosecution Insights
Last updated: November 04, 2026
Application No. 17/494,632

Early Detection of Cancer, Recurrence Monitoring and Companion Diagnostics via Liquid Biopsy

Non-Final OA §103§112
Filed
Oct 05, 2021
Priority
Oct 06, 2020 — provisional 63/088,131
Examiner
WOITACH, JOSEPH T
Art Unit
1687
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Crystal Genetics Inc.
OA Round
1 (Non-Final)
49%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
202 granted / 409 resolved
-10.6% vs TC avg
Strong +27% interview lift
Without
With
+27.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 8m
Avg Prosecution
59 currently pending
Career history
472
Total Applications
across all art units

Statute-Specific Performance

§101
37.2%
-2.8% vs TC avg
§103
20.4%
-19.6% vs TC avg
§102
2.8%
-37.2% vs TC avg
§112
26.5%
-13.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 409 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim status No claim amendments were filed. Original claims 1-20 filed 10/5/2021 are pending. Election/Restriction Applicant's election with traverse of Group I in the reply filed on 3/31/2026 is acknowledged. The traversal is on the ground(s) that they are not patentably distinct. This is found persuasive because upon initial review of the requirement of the limitations and the search of the art, it does not appear to be an undue burden to examine all the methods while only different in the final steps after the assessment. Accordingly, the restriction requirement is withdrawn. It is noted that Applicants did not respond to the species requirement setting forth patentably distinct species of: Feature of interest (foi) (generically in claims 7-10 for example); Sample qualification system (sqs) (generically in claims 11-12); Feature isolation step (fis) (generically in claims 13-16); and Feature molecular analysis (fms) (generically in claims 17-18). While it is maintained that the species appear to require separate search and consideration, for compact prosecution the species requirement is withdrawn. Priority This application filed 10/5/2021 claims benefit to US Provisional application 63/088131 filed 10/6/2020. Information Disclosure Statement No IDS has been filed. The listing of references in the specification is not a proper information disclosure statement. See reference section starting on page 55. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, claims 1, 19 and 20 recite the limitations "the Enriched Biological Sample", “the Qualification of Biological Sample” and “the isolated cells”. There is insufficient antecedent basis for this limitation in the claim. While the claims provide for generic steps for purification and analysis, they fail to clearly support the metes and bounds of what is performed and what would be present or required or excluded from each of these limitations. Dependent claims are included as they do not address the issue of the independent claims, and require the clear metes and bounds of each of them. More clearly providing detailed steps or amendments to the claims would address the basis of the rejection. Claim Objections Applicant is advised that should claim 1 be found allowable, claim 19 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). In this case claims 1 and 19 have the same six steps and result in the same final ‘declaring’ step. Claim 20 has the same first 5 steps but provides for slightly different calculation step as a final step. Each of claims 1, 19 and 20 are provided for completeness and clarity of the record. 1 A method for Detection of a Condition of Interest (Col) in a Subject, said method comprising the steps of: obtaining a Biological Sample from said Subject; and performing Enrichment operation on at least a portion of the Biological Sample for the Features of Interest (Fol) to arrive at the Enriched Biological Sample (EBS); and feeding at least a portion of the EBS to a Sample Qualification System (SQS) to label the Biological Sample as Likely (Qualified) or Not Likely (not Qualified) in relation to said Col; and passing at least a portion of the said Qualified Samples to the Feature Isolation Step (FIS) to arrive at the Isolated Cells; and Subjecting at least a portion the Isolated Cells to Feature Molecular Analysis (FMA); and declaring the state of the Subject as Detected for the said Col if the FMA results in a positive call. 19 A method for Detection of a Condition of Interest (Col) in a Subject, said method comprising the steps of: obtaining a Biological Sample from said Subject; and performing Enrichment operation on at least a portion of the Biological Sample for the Features of Interest (Fol) to arrive at the Enriched Biological Sample (EBS); and feeding at least a portion of the EBS to a Sample Qualification System (SQS) to assign a non-binary Likelihood to the Qualification of Biological Sample in relation to said Col; and passing at least a portion of the said Sample with high Likelihood to the Feature Isolation Step (FIS) to arrive at the Isolated Cells; and Subjecting at least a portion the Isolated Cells to Feature Molecular Analysis (FMA); and declaring the state of the Subject as Detected for the said Col if the FMA results in a positive call. 20 A method for Detection of a Condition of Interest (Col) in a Subject, said method comprising the steps of: obtaining a Biological Sample from said Subject; and performing Enrichment operation on at least a portion of the Biological Sample for the Features of Interest (Fol) to arrive at the Enriched Biological Sample (EBS); and feeding at least a portion of the EBS to a Sample Qualification System (SQS) to assign a non-binary Likelihood to the Qualification of Biological Sample in relation to said Col; and passing at least a portion of the said Sample to the Feature Isolation Step (FIS) to arrive at the Isolated Cells; and subjecting at least a portion the Isolated Cells to Feature Molecular Analysis (FMA) to arrive at a Likelihood based on FMA, and calculate an overall Likelihood, based on the Likelihoods defined in SQS and FMA, for the said Subject to be related to the said Col. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-20 are rejected under 35 U.S.C. 103 as being unpatentable over Gadalla et al., Mone (2018) and Lopresti et al. (2019). Independent claim 1 provides six steps comprising: 1 obtaining a sample; 2 enriching from the sample based on a feature; 3 labeling the sample; 4 isolating based on the label; 5 providing further analysis based in part on the feature of interest; and 6 interpreting for the presence or absence of the further analysis. Dependent claims provide that the condition being analyzed is cancer from humans and that the sample is circulating tumor cell present in the blood. In light of the guidance of the specification and the art, the steps encompass providing a sample, isolating cells from the sample, labelling the cells and analyzing the labelled (or unlabeled cells) by FACS and then performing any additional analysis on the separated/isolated cells. At the time, using FACS and labelling cells with detectable markers to analyzing cancer and circulating cells from the blood were well known. For example, Gadalla et al. provide for methods for the use of flow cytometry as a widely applied approach for exploratory immune profiling and biomarker discovery in cancer and other diseases. Gadalla provide an overview of results where they compare and validate the accuracy and reproducibility of CyTOF against flow cytometry as a reliable analytic tool for human PBMC and tumor tissues for cancer clinical trials; and provide for 40+ parameter CyTOF panel and demonstrate that compared to flow cytometry, CyTOF yields analogous quantification of cell lineages in conjunction with markers of cell differentiation, function, activation, and exhaustion for use with fresh and viably frozen PBMC or tumor tissues. Gadalla et al. provide for each of the steps comprised by the breadth of the present claims but do not specifically use the language. Amy Mone is provided as further evidence that markers for circulating cells representing several cancer types that could be detected in the blood were known showing that a single blood test that screens for eight common cancers. Similar to Gadalla et al. Lopresti et al. is provided to demonstrate that sensitive and easy screening for circulating tumor cells by flow cytometry were known. Each of the references provide a listing of known and useful markers for screening and isolation, and provide further analysis of the isolate for validation of the methodology described. Given the breadth of the claims and large body of knowledge in the art for studying and validating cancer based on circulating cells in the blood, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to use FACS to label, analyze and provide assessment of cancer in a subject based on circulating cells in the blood. One having ordinary skill in the art would have been motivated to use blood as a source of sample and methods such as FACS for reliable determination of markers present in or on the cells being analyzed and the known correlations of the markers with various types of cancer they represent. Given the results and overview each of the citations provide, there would have been a reasonable expectation of success to analyze blood for circulating cancer cells with known methods and labels, and provide a summary of the analysis of a subjects blood and possible diagnosis of a condition for the subject. Thus, the claimed invention as a whole was clearly prima facie obvious. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph T Woitach whose telephone number is (571)272-0739. The examiner can normally be reached Mon-Fri; 8:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Karlheinz R Skowronek can be reached at 571 272-9047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Joseph Woitach/Primary Examiner, Art Unit 1687
Read full office action

Prosecution Timeline

Oct 05, 2021
Application Filed
Jun 04, 2025
Response after Non-Final Action
Mar 31, 2026
Examiner Interview Summary
Mar 31, 2026
Applicant Interview (Telephonic)
Sep 29, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781258
METHODS FOR NORMALIZATION AND QUANTIFICATION OF SEQUENCING DATA
6y 0m to grant Granted Nov 03, 2026
Patent 12763165
METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS
5y 10m to grant Granted Oct 13, 2026
Patent 12762187
Inexact Search Acceleration
5y 7m to grant Granted Oct 13, 2026
Patent 12742212
METHOD FOR PREDICTING AND EVALUATING ANTIMICROBIAL THERAPY WHEN MOLECULAR PCR DIAGNOSTIC TESTING RESULTS YIELD MULTI-ORGANISMS AND MULTI-RESISTANT BACTERIA FROM A SINGLE DNA SAMPLE
4y 5m to grant Granted Sep 22, 2026
Patent 12738344
METHOD FOR FINDING VARIANTS FROM TARGETED SEQUENCING PANELS
6y 11m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
49%
Grant Probability
77%
With Interview (+27.4%)
4y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 409 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month